Arbutus Biopharma (ABUS) Operating Leases (2019 - 2025)

Arbutus Biopharma (ABUS) has reported Operating Leases for 7 consecutive years, with $199000.0 the latest figure, recorded in Q4 2025.

• Quarterly Operating Leases fell 75.31% year-over-year to $199000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $199000.0 (down 75.31% YoY) and the FY2025 annual result came in at $199000.0, down 75.31% from the prior year.
• Operating Leases slipped to $199000.0 in Q4 2025 per ABUS's latest filing, from $391000.0 in the prior quarter.
• Over the last five years, Operating Leases for ABUS reached as high as $2.5 million in Q1 2021 and fell as low as $199000.0 in Q4 2025.
• A 5-year average of $1.5 million and a median of $1.6 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2021 — Operating Leases slipped 13.67% — and 2025, when it plunged 75.31%.
• Year by year, Operating Leases stood at $2.2 million in 2021, then decreased by 18.65% to $1.8 million in 2022, then declined by 26.01% to $1.3 million in 2023, then tumbled by 39.99% to $806000.0 in 2024, then tumbled by 75.31% to $199000.0 in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $199000.0, $391000.0, and $575000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.